mortality/aging
|
• relatively lower survival rate
|
growth/size/body
|
• smaller size and delayed growth features compared to controls at 4 weeks of age
• administration of a PPARG inhibitor partially rescues the reduction in body size
|
skeleton
|
• increase in bone marrow adipose tissue accumulation in both primary and secondary ossification centers
• number and density of bone marrow adipocytes are apparently elevated
• accumulation of adipose in the marrow is more striking in females
|
|
• cranial bone hypoplasia at 2 and 4 weeks of age
|
|
• slightly shortened growth plate
|
|
• at 4 weeks of age in the femur
|
|
• at 4 weeks of age
|
|
• treatment with a PPARG inhibitor partially rescues the cortical bone phenotypes
|
|
• at 4 weeks of age
|
|
• treatment with a PPARG inhibitor partially rescues the trabecular phenotypes
|
|
• at 4 weeks of age
|
|
• in the femur at 4 weeks of age
|
|
• at 4 weeks of age
|
|
• lower degree of mineralization in the cranial and maxillofacial bones at P2
• slower bone mineral apposition rate at 4 weeks of age
|
|
• slower bone formation rate
|
hematopoietic system
|
• bone marrow mesenchymal stem cells show reduced osteogenic and increased adipogenic potential in vitro
|
adipose tissue
|
• increase in bone marrow adipose tissue accumulation in both primary and secondary ossification centers
• number and density of bone marrow adipocytes are apparently elevated
• accumulation of adipose in the marrow is more striking in females
|
craniofacial
|
• cranial bone hypoplasia at 2 and 4 weeks of age
|
limbs/digits/tail
|
• at 4 weeks of age
|
short limbs
(
J:336448
)
|
• shorter forelimbs and hindlimbs at P2
|


Analysis Tools